期刊： THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021; 13 ()
Introduction: Endocrine therapy and cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6i) are standard treatment options for hormone receptor positiv......
期刊： THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021; 13 ()
Background: EGFR mutation is a common oncogene driver in East Asians with lung adenocarcinoma (LUAD), conferring a favorable prognosis with effective ......
期刊： THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021; 13 ()
Background: Eribulin is a nontaxane microtubule inhibitor approved in China for patients with advanced breast cancer who show progression after > 2......
期刊： THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021; 13 ()
Background: Tumor progression following endocrine therapy is considered to indicate resistance to endocrine drugs due to a variety of mechanisms. An i......
期刊： THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021; 13 ()
Background: Although dual blockade HER2-based neoadjuvant chemotherapy is associated with excellent outcomes for human epidermal growth factor recepto......
期刊： THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021; 13 ()
Background: There are limited comparisons of first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) in large, real-world cohorts of non-s......
期刊： THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021; 13 ()
Background: Pucotenlimab is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb) with a S22......
期刊： THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021; 13 ()
Immune checkpoint inhibitors (ICIs) have come to play an increasingly prominent role in the treatment of lung cancer, and some are recommended as a fi......
期刊： THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021; 13 ()
Background: Resistance or even hyper-progression to immune checkpoint inhibitors (ICIs) manifesting as accelerated disease progression or death has im......
期刊： THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021; 13 ()
Background: Axillary node status is used in clinical practice to guide the selection of axillary surgery in breast cancer patients. However, to date, ......
期刊： THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021; 13 ()
Background: There is no standard therapy for metastatic biliary tract carcinoma (BTC) refractory to first-line chemotherapy. Apatinib, a VEGFR2 tyrosi......
期刊： THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021; 13 ()
Neuroendocrine tumors (NETs) are rare, heterogeneous, often indolent tumors that predominantly originate in the lungs and gastrointestinal tract. An u......
期刊： THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021; 13 ()
Background: This multicenter study aimed to reveal the genetic spectrum of colorectal cancer (CRC) with deficient mismatch repair (dMMR) and build a s......
期刊： THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021; 13 ()
Background: (99m)Technetium labeled methylene diphosphonate bone scans (BSs) are commonly used to monitor disease progression in bone for patients wit......
